glp-1 drugs safety risks in the market: an update on weight loss medication, May 2026 – Partnership for Safe Medicines Low Dose GLP-1 for Inflammation:
Description
The most common designs are observational studies
Ozempic changed the conversation around weight loss in a way that almost nothing has in the past twenty years
Does it have any impact
Theyre everywhere
GRADE: LOW certainty)
Results At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2
